Fisiopharma
Fisiopharma is a pharmaceutical company founded in 1989, specializing in the development and production of injectable drugs. It is committed to quality, innovation, and international expansion, with a focus on contract development and manufacturing (CDMO) services for pharmaceutical companies worldwide. The company emphasizes sustainability, regulatory compliance, and long-term partnerships with clients.
Industries
Nr. of Employees
medium (51-250)
Fisiopharma
Products
Contract manufacture of sterile injectable products
Contract development and manufacture of sterile injectable dosage forms (small‑volume liquids, suspensions, sterile powders) for clinical and commercial supply.
Analytical and microbiological testing services
In‑house chemical‑physical and microbiological testing supporting release, stability and development activities.
Contract manufacture of sterile injectable products
Contract development and manufacture of sterile injectable dosage forms (small‑volume liquids, suspensions, sterile powders) for clinical and commercial supply.
Analytical and microbiological testing services
In‑house chemical‑physical and microbiological testing supporting release, stability and development activities.
Services
Development and optimization of injectable formulations and manufacturing processes, including small‑scale trials, DoE and preparation of pilot material for validation.
Chemical and microbiological method development and validation with transfer to manufacturing or client laboratories.
Execution of process validations, media‑fill studies, equipment qualification and sterilizer validation for regulatory compliance.
Contract manufacturing of clinical, pilot and commercial lots of sterile injectables across multiple batch sizes and formats.
Secondary packaging, serialization and aggregation for regulated markets with capability to support market‑specific requirements.
Preparation of regulatory submissions and strategic support for registrations in Europe, USA and other regions, including eCTD conversion.
Development and optimization of injectable formulations and manufacturing processes, including small‑scale trials, DoE and preparation of pilot material for validation.
Chemical and microbiological method development and validation with transfer to manufacturing or client laboratories.
Execution of process validations, media‑fill studies, equipment qualification and sterilizer validation for regulatory compliance.
Contract manufacturing of clinical, pilot and commercial lots of sterile injectables across multiple batch sizes and formats.
Secondary packaging, serialization and aggregation for regulated markets with capability to support market‑specific requirements.
Preparation of regulatory submissions and strategic support for registrations in Europe, USA and other regions, including eCTD conversion.
Expertise Areas
- CDMO for sterile injectable drugs
- Aseptic fill‑finish and terminal sterilization
- Formulation and process development for injectables
- Analytical method development and validation
Key Technologies
- Aseptic fill‑finish
- Terminal sterilization
- Sterile powder vial filling
- Single‑use process systems
News & Updates
Fisiopharma participates in CDMO Live 2025
Fisiopharma will attend the CDMO Live 2025 event in Rotterdam on May 7-8, 2025, to meet new clients and partners.
Fisiopharma at DCAT Week 2025
Participation in the international business development event in New York from March 17-20, 2025.
Fisiopharma at CPhI Milano 2024
Participation in the pharmaceutical event in September 2024 to showcase development and production capabilities.
Fisiopharma at DCAT Week 2024
Participation in the New York event in March 2024, engaging with US clients and partners.
Fisiopharma at CPhI Frankfurt 2022
Participation in the major pharmaceutical event in November 2022, connecting with global clients.
Fisiopharma awarded by Yifan Pharmaceuticals in 2022
Received the Yifan President Award for achievements including approvals from US FDA, Brazil ANVISA, and Libyan Health Authority.
Fisiopharma participates in CDMO Live 2025
Fisiopharma will attend the CDMO Live 2025 event in Rotterdam on May 7-8, 2025, to meet new clients and partners.
Fisiopharma at DCAT Week 2025
Participation in the international business development event in New York from March 17-20, 2025.
Fisiopharma at CPhI Milano 2024
Participation in the pharmaceutical event in September 2024 to showcase development and production capabilities.
Fisiopharma at DCAT Week 2024
Participation in the New York event in March 2024, engaging with US clients and partners.
Fisiopharma at CPhI Frankfurt 2022
Participation in the major pharmaceutical event in November 2022, connecting with global clients.
Fisiopharma awarded by Yifan Pharmaceuticals in 2022
Received the Yifan President Award for achievements including approvals from US FDA, Brazil ANVISA, and Libyan Health Authority.